| Dr Woodwin Michael Weeks, DO | |
|
1 Magnolia Ct, Moultrie, GA 31768-6764 | |
| (229) 502-9769 | |
| Not Available |
| Full Name | Dr Woodwin Michael Weeks |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 14 Years |
| Location | 1 Magnolia Ct, Moultrie, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053612325 | NPI | - | NPPES |
| 003132749A | Medicaid | GA | |
| 003132749D | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 68866 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Amedisys Home Health | Tifton, GA | Home health agency |
| Colquitt Regional Medical Center | Moultrie, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Colquitt Regional Hospitalists, Llc | 0749568780 | 21 |
| Colquitt Regional Medical Center | 6204821796 | 17 |
News Archive
In 2004, the United States Food and Drug Administration approved a radiofrequency identification (RFID) device that is implanted under the skin of the upper arm of patients and that stores the patient's medical identifier.
SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced preliminary data from its ongoing open-label Phase 1/2 clinical trial of SAGE-547, an allosteric modulator of GABAA receptors, in patients with super-refractory status epilepticus (SRSE).
The coronavirus probably has a stronger ability to spread than the World Health Organization has estimated so far. This according to a review of previous studies of the coronavirus' transmissibility performed not least by researchers at Umeå University in Sweden.
Sangamo BioSciences, Inc. announced the publication of data demonstrating the preclinical efficacy of a human stem cell therapy for human immunodeficiency virus (HIV) based on its proprietary zinc finger DNA-binding protein nuclease (ZFN) technology.
Researchers at UC Davis have determined that surgical biopsies can be safely performed on select patients with late-stage non-small cell lung cancer, which should enhance their access to drugs that target specific genetic mutations such as epidermal growth factor receptor (EGFR).
› Verified 9 days ago
| Entity Name | Colquitt Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912099094 PECOS PAC ID: 6204821796 Enrollment ID: O20040415000368 |
News Archive
In 2004, the United States Food and Drug Administration approved a radiofrequency identification (RFID) device that is implanted under the skin of the upper arm of patients and that stores the patient's medical identifier.
SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced preliminary data from its ongoing open-label Phase 1/2 clinical trial of SAGE-547, an allosteric modulator of GABAA receptors, in patients with super-refractory status epilepticus (SRSE).
The coronavirus probably has a stronger ability to spread than the World Health Organization has estimated so far. This according to a review of previous studies of the coronavirus' transmissibility performed not least by researchers at Umeå University in Sweden.
Sangamo BioSciences, Inc. announced the publication of data demonstrating the preclinical efficacy of a human stem cell therapy for human immunodeficiency virus (HIV) based on its proprietary zinc finger DNA-binding protein nuclease (ZFN) technology.
Researchers at UC Davis have determined that surgical biopsies can be safely performed on select patients with late-stage non-small cell lung cancer, which should enhance their access to drugs that target specific genetic mutations such as epidermal growth factor receptor (EGFR).
› Verified 9 days ago
| Entity Name | Phoebe Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487899464 PECOS PAC ID: 8426112350 Enrollment ID: O20090121000583 |
News Archive
In 2004, the United States Food and Drug Administration approved a radiofrequency identification (RFID) device that is implanted under the skin of the upper arm of patients and that stores the patient's medical identifier.
SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced preliminary data from its ongoing open-label Phase 1/2 clinical trial of SAGE-547, an allosteric modulator of GABAA receptors, in patients with super-refractory status epilepticus (SRSE).
The coronavirus probably has a stronger ability to spread than the World Health Organization has estimated so far. This according to a review of previous studies of the coronavirus' transmissibility performed not least by researchers at Umeå University in Sweden.
Sangamo BioSciences, Inc. announced the publication of data demonstrating the preclinical efficacy of a human stem cell therapy for human immunodeficiency virus (HIV) based on its proprietary zinc finger DNA-binding protein nuclease (ZFN) technology.
Researchers at UC Davis have determined that surgical biopsies can be safely performed on select patients with late-stage non-small cell lung cancer, which should enhance their access to drugs that target specific genetic mutations such as epidermal growth factor receptor (EGFR).
› Verified 9 days ago
| Entity Name | Colquitt Regional Hospitalists, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851840912 PECOS PAC ID: 0749568780 Enrollment ID: O20161026002551 |
News Archive
In 2004, the United States Food and Drug Administration approved a radiofrequency identification (RFID) device that is implanted under the skin of the upper arm of patients and that stores the patient's medical identifier.
SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced preliminary data from its ongoing open-label Phase 1/2 clinical trial of SAGE-547, an allosteric modulator of GABAA receptors, in patients with super-refractory status epilepticus (SRSE).
The coronavirus probably has a stronger ability to spread than the World Health Organization has estimated so far. This according to a review of previous studies of the coronavirus' transmissibility performed not least by researchers at Umeå University in Sweden.
Sangamo BioSciences, Inc. announced the publication of data demonstrating the preclinical efficacy of a human stem cell therapy for human immunodeficiency virus (HIV) based on its proprietary zinc finger DNA-binding protein nuclease (ZFN) technology.
Researchers at UC Davis have determined that surgical biopsies can be safely performed on select patients with late-stage non-small cell lung cancer, which should enhance their access to drugs that target specific genetic mutations such as epidermal growth factor receptor (EGFR).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Woodwin Michael Weeks, DO Po Box 2876, Moultrie, GA 31776-2876 Ph: (229) 502-9769 | Dr Woodwin Michael Weeks, DO 1 Magnolia Ct, Moultrie, GA 31768-6764 Ph: (229) 502-9769 |
News Archive
In 2004, the United States Food and Drug Administration approved a radiofrequency identification (RFID) device that is implanted under the skin of the upper arm of patients and that stores the patient's medical identifier.
SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced preliminary data from its ongoing open-label Phase 1/2 clinical trial of SAGE-547, an allosteric modulator of GABAA receptors, in patients with super-refractory status epilepticus (SRSE).
The coronavirus probably has a stronger ability to spread than the World Health Organization has estimated so far. This according to a review of previous studies of the coronavirus' transmissibility performed not least by researchers at Umeå University in Sweden.
Sangamo BioSciences, Inc. announced the publication of data demonstrating the preclinical efficacy of a human stem cell therapy for human immunodeficiency virus (HIV) based on its proprietary zinc finger DNA-binding protein nuclease (ZFN) technology.
Researchers at UC Davis have determined that surgical biopsies can be safely performed on select patients with late-stage non-small cell lung cancer, which should enhance their access to drugs that target specific genetic mutations such as epidermal growth factor receptor (EGFR).
› Verified 9 days ago
Lisa Ann Young, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Magnolia Ct, Moultrie, GA 31768 Phone: 229-502-9769 Fax: 928-338-5508 | |
Dr. Arthur Clifford Marsh, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1315 S Main St, Moultrie, GA 31768 Phone: 229-985-1334 Fax: 229-891-2508 | |
Dr. Gary Wade Swartzentruber, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8 Laurel Ct, Moultrie, GA 31768 Phone: 229-891-9016 | |
Dr. Michael A Kelley, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3131 S Main St, Moultrie, GA 31768 Phone: 229-502-9782 Fax: 229-891-9567 | |
Michael Magat, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3131 S Main St, Moultrie, GA 31768 Phone: 229-985-3420 Fax: 229-985-3018 | |
Dr. Dale Mcgregor, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 3131 S Main St, Moultrie, GA 31768 Phone: 229-985-3420 |